Oncopeptides publishes prospectus relating to the rights issue

MARKN.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

On 13 March 2024, Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) announced that the Board of Directors has decided to carry out a fully guaranteed rights issue of approximately SEK 314 million before deduction of costs related to the rights issue (the “Rights Issue”).

The prospectus relating to the Rights Issue has today, 17 April 2024, been approved and registered by the Swedish Financial Supervisory Authority and is available on Oncopeptides’ website, https://oncopeptides.com/en/investors/share-issues/rights-issue-may-2024/ and on Carnegie Investment Bank AB (publ)’s website, www.carnegie.se. The prospectus will also be made available on the Swedish Financial Supervisory Authority’s website, www.fi.se.
 
Shareholders with nominee registered holdings are referred to their respective nominees for specific information and instructions. Shareholders with directly registered holdings receive information by mail and can find subscription forms with and without subscription rights on Oncopeptides’ and Carnegie's websites.
 
The subscription period starts on 19 April 2024, and runs up until 3 May 2024. The complete timetable for the rights issue is available in the prospectus and on Oncopeptides’ website, https://oncopeptides.com/en/investors/share-issues/rights-issue-may-2024/.
 
The Company has been informed that three investors have undertaken to acquire and subscribe for all subscription rights that Industrifonden is entitled to receive per its existing holding, corresponding to 8,285,258 subscription rights.

Advisors
Carnegie Investment Bank AB (publ), DNB Markets, a part of DNB Bank ASA, Sweden Branch and Zonda Partners act as Joint Bookrunners in connection with the Rights Issue. Advokatfirman Vinge KB is legal adviser to the Company and Baker McKenzie is legal adviser to the Joint Bookrunners in connection with the Rights Issue.

Datum 2024-04-17, kl 14:10
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!